Novo Nordisk said on Wednesday that she would start selling her drug for Wegovy weight loss at a discount price of $ 499 a month for paying money, as she accumulates in the competitive dynamics of the US overweight drug market.
The measure comes just over a week after rival Eli Lilly lowered the price for his Zepbound weight loss drug vial by $ 50 or more and expanded the range of doses sold online through its direct customer site.
Eli Lilly began to offer vials of the two lower doses of Zepbound, which is usually sold in automatic injection pens in August.
Now it sells vials from everyone, but two doses with higher strength of the medicine through Lillydirect. The lowest dose costs $ 349 a month and others cost $ 499 a month.
Novo said that his deducted Wegovy would be available in pens of all hard dosage points for unsecured patients or patients acceptable with trade insurance who have no coverage of overweight medication through his Novocare pharmacy program.
Drugmaker Danish will also provide home distribution for the medicine, which can cost patients more than $ 1,000 a month if they have no health insurance coverage.
The shares listed by Novo’s SH.BA increased 4.2% to $ 91.16 in the morning trading.
The united pharmacies that have sold hundreds of thousands of Wegovy doses of copies while the drugs were in absentia and time to produce them.
The Food and Drug Administration in February removed Wegovy from the list of its absence and told the components to rest the selling of their cheaper copies in the coming months after removing Zepbound in December.
“With both Lillydirect and Novocare set, both Lilly and Novo look to cut composite pharmacies, which have received some of the considerable requirements of their product,” BMO analyst Evan Seigerman said in a research note.
The drug ingredients led by the Industry Trade Group, the Association of Outsourcing Transfer Facilities FDA last month for its decision to remove Wegovy from its list of drugs in absentia.
They previously claim the agency’s statement that Lilly’s Tirzepatide Drugs, including Zepbound, were no longer in short supply.
The FDA said last month that some pharmacies composed until the court made its decision in the previous case to stop the sale of composite Tirzepatide, but did not say if the same deadline is for Wegovy copies.
The shares of the provider of the Telehealth Hims & Hers, who sells complicated wegovy versions, fell 4.2% to $ 38.76 in the morning trade.
Company shares almost tripled last year, giving it a $ 9 billion market capitalization.
#Novo #Nordisk #sell #Wegovy #month #paying #customers
Image Source : nypost.com